MOG antibody disease

MOG (myelin oligodendrocyte glycoprotein) antibody disease (MOGAD) or MOG antibody-associated encephalomyelitis (MOG-EM)[1] is an inflammatory demyelinating disease of the central nervous system. Serum anti-myelin oligodendrocyte glycoprotein antibodies are present in up to half of patients with an acquired demyelinating syndrome and have been described in association with a range of phenotypic presentations, including acute disseminated encephalomyelitis, optic neuritis, transverse myelitis, and neuromyelitis optica.[2]

  1. ^ Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. (May 2018). "MOG encephalomyelitis: international recommendations on diagnosis and antibody testing". Journal of Neuroinflammation. 15 (1) 134. doi:10.1186/s12974-018-1144-2. PMC 5932838. PMID 29724224.
  2. ^ Ramanathan S, Dale RC, Brilot F (April 2016). "Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination". Autoimmunity Reviews. 15 (4): 307–324. doi:10.1016/j.autrev.2015.12.004. PMID 26708342.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.